Related Experiment Video
Updated: Nov 4, 2025
Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
Published on: May 31, 2024
Effect of Topical Brimonidine 0.15% on Conjunctival Injection after Strabismus Surgery in Children
Dong Hyun Kim1, Hee Kyung Yang1, Sang Beom Han2
1Department of Ophthalmology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
Insights
Topical brimonidine 0.15% effectively reduces conjunctival injection after strabismus surgery in children. This safe treatment showed no adverse effects or changes in intraocular pressure, improving recovery.
Area of Science:
- Ophthalmology
- Pediatric Surgery
Background:
- Strabismus surgery in children can lead to significant conjunctival injection.
- Managing postoperative inflammation and discomfort is crucial for patient recovery.
Purpose of the Study:
- To evaluate the efficacy and safety of topical brimonidine 0.15% in reducing conjunctival injection post-strabismus surgery in pediatric patients.
Main Methods:
- Retrospective analysis of 63 Korean children undergoing strabismus surgery for intermittent exotropia.
- Patients received topical brimonidine 0.15% post-surgery for up to 4 weeks.
- Objective assessment of conjunctival injection using automated image scoring, compared to a control group.
Main Results:
- Significantly lower conjunctival injection scores at 4 weeks in the brimonidine group compared to controls (P = 0.008 for recession, P = 0.046 for resection).
- No significant differences in intraocular pressure between groups.
- No reported adverse effects, including dry mouth, fatigue, sedation, or hypotension.
Conclusions:
- Topical brimonidine 0.15% is an effective and safe adjunctive treatment for reducing conjunctival injection after pediatric strabismus surgery.
- The medication offers a favorable safety profile with no impact on intraocular pressure or systemic side effects.
Purpose:
To investigate the effects of topical brimonidine 0.15% instillation on conjunctival injection after strabismus surgery in children.
Methods:
We retrospectively analyzed 63 Korean children who underwent strabismus surgery for intermittent exotropia. Patients received topical brimonidine 0.15% after surgery for up to 4 weeks. Conjunctival injection was objectively assessed using a software that automatically scored the region of interest from the image of the bulbar conjunctiva. Conjunctival injection scores were compared with those of the control group who were not prescribed topical brimonidine.
Results:
The mean scores of conjunctival injection after rectus muscle recession and resection were significantly lower in the brimonidine group than the controls at 4 weeks after surgery (P = 0.008 and 0.046, respectively). There was no significant difference in intraocular pressure between the two groups. No adverse effects, such as dry mouth, fatigue/drowsiness, headache, sedation, hypotension, or bradycardia, were reported.
Conclusions:
Administration of topical brimonidine 0.15% after strabismus surgery is efficacious and safe in reducing postoperative conjunctival injection.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:28Angle Closure Glaucoma: Treatment